Ironwood Pharmaceuticals (IRWD) vs Pharming Group N.V. (PHAR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Ironwood Pharmaceuticals (IRWD) has outperformed Pharming Group N.V. (PHAR) over the past year, gaining 144.9% versus a loss of 34.2%. Over five years, PHAR leads with a +2.2% price change compared with -71.7% for IRWD. Pharming Group N.V. is the larger company by market cap ($674.5 million vs $639.5 million), about 1.1 times the size.
On valuation, Ironwood Pharmaceuticals trades at a lower forward P/E (2.6x vs 31.0x for Pharming Group N.V.).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IRWD | PHAR |
|---|---|---|
| Share price | $3.87 | $9.53 |
| Market cap | $639.48M | $674.52M |
| 1-day change | +3.20% | -1.24% |
| YTD return | +14.84% | -45.39% |
| 1-year return | +144.94% | -34.22% |
| 5-year return | -71.67% | +2.22% |
| P/E ratio (TTM) | 5.03 | 73.31 |
| Forward P/E | 2.58 | 31.04 |
| EPS (TTM) | $0.77 | $0.13 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.78 | $21.34 |
| 52-week low | $1.41 | $9.44 |
| Distance from 52-week high | -33.04% | -55.34% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +57.62% | +260.44% |
| Average volume | 2.02M | 22.84K |
| Shares outstanding | 165.24M | 70.78M |
| Employees | 100 | 407 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IRWD has outperformed PHAR by 179.2 percentage points over the past year.
- Pharming Group N.V. trades at a higher earnings multiple (73.3x vs 5.0x trailing P/E).
About Ironwood Pharmaceuticals
IRWD stock →Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It sells linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well as for pediatric patients suffering from functional constipation under the LINZESS and CONSTELLA names.
Health Care · Biotechnology: Pharmaceutical Preparations · 100 employees
About Pharming Group N.V.
PHAR stock →Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Health Care · Biotechnology: Pharmaceutical Preparations · 407 employees
IRWD vs PHAR FAQ
Which is bigger, Ironwood Pharmaceuticals or Pharming Group N.V.?
Pharming Group N.V. (PHAR) is larger, with a market capitalization of $674.52M compared with $639.48M for Ironwood Pharmaceuticals (IRWD).
Which stock has performed better over the past year, IRWD or PHAR?
IRWD returned +144.94% over the past 12 months, compared with -34.22% for PHAR (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, IRWD or PHAR?
IRWD has the lower trailing P/E at 5.0, versus 73.3 for PHAR. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Ironwood Pharmaceuticals and Pharming Group N.V. in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.